

BLOOM BURTON
AWARD GALA

VIRTUAL EXPERIENCE

02. WELCOME LETTER

Brian Bloom and Jolyon Burton

Poul Sorenson | 2019 Bloom Burton Award Winner

05. MESSAGE FROM THE PRIME MINISTER

Justin Trudeau

07. MESSAGE FROM THE PREMIER

Doug Ford

09. MESSAGE FROM THE MAYOR

John Tory

12. FINALIST PROFILES

Gordon Keller

Arun Menawat

Simon Pimstone

20. JUDGES PANEL PROFILES

Michael Altman

Chris Arendt

Karen Bernstein

Carl Gordon

Dennis Purcell

Melinda Richter

Camille Samuels

CONTENT

WELCOME

Thank you for joining our virtual presentation of the 2020 Bloom Burton Award Gala, an event to celebrate leaders who have demonstrated excellence in the innovative Canadian healthcare sector in the previous year.

We received many nominations for the 2020 Bloom Burton Award from the public-at-large and then our international judging panel selected the three finalists, each of whom deserves our recognition tonight: Gordon Keller of BlueRock Therapeutics, Arun Menawat of Profound Medical and Simon Pimstone of Xenon Pharmaceuticals.

We are grateful to everyone who gave their time and effort to this year's Bloom Burton Award and recognize the extra efforts all involved made to contribute safely during the pandemic. We also thank everyone in our healthcare industry, working tirelessly to provide humanity with solutions against all diseases – ever more so evident during the global pandemic of 2020. Thank you for your efforts and your courage.

Let us raise a virtual glass to toast our finalists, our industry and its important work!



BRIAN BLOOM



JOLYON BURTON

POUL SORENSON

Johal Chair in Childhood Cancer Research
Professor, Department of Pathology, University of British Columbia
Distinguished Scientist, BC Cancer Research Centre

I am absolutely delighted and deeply honored to be involved in the 2020 Bloom Burton Award presentation for health care innovation in Canada. I want to first extend warm and humble congratulations to each of the finalists, as well as to your teams and of course, your families. Each of your contributions has been peer-reviewed by a panel of international experts in the field, and they have picked you as Canada- and indeed world-leading examples of what it takes to be a winner in this field; i.e. delivering health care innovations that represent bold new approaches in what is a very complicated business, and that help pump-prime the Canadian economy. This is a proud moment for all of you!

I am writing this letter because, much to my surprise, I was awarded the 2019 Bloom Burton Award. Why was I surprised, because I am a health care researcher, and unlike many of you, not primarily involved in industry nor in developing or running a biotech company. Twenty years ago, and with lots of hard follow-up work by a superb team, my research lab made a series of discoveries that have, several decades later, led to drug developments in clinical oncology that now help people all over world suffering from malignant diseases. Having thought about being the Bloom Burton Award winner for the past year, I have come to realize that actually, we are all part of a huge team, and delivery of health care innovations to the clinic is really a multi-segment pipeline that needs all sorts of expertise along the way. Yes, we need basic science discoveries that identify new potential drug targets or novel devices and other interventions to prevent or treat human illnesses. However, we also need excellent industry partners to come in and carry the ball across the finish line.

WELCOME

4 Welcome

In recent years, we have seen unprecedented advances in biomedical science, technology and computational science. Yet, in spite of the accelerated pace of fundamental discoveries across all areas of biomedicine, the timeline for translating this knowledge into concrete improvements in clinical care continues to lag dramatically. In the words of Oxford's Sir Gordon Duff, "The great challenge now is to translate this new knowledge into health gains for individuals and our communities". This can only happen if the academic and industry communities work together. This is why the creation of the Bloom Burton Award by Brian and Jolyon is so critical and timely, as it highlights and indeed credentializes the need for us to work together. I am deeply honored to have made at least a small contribution to help them in achieving their profound vision.

I wish you each a wonderful evening, although I wish we could have done this in person. Again, huge congratulations to each of the nominees and to the winner. You should each be extremely proud of what your achievements mean for global health care delivery.

With best wishes.

A handwritten signature in black ink that reads "Poul Sorensen". The signature is written in a cursive style and is positioned to the left of a vertical line.

POUL SORENSEN



THE RT. HON. JUSTIN P.J. TRUDEAU, P.C., M.P.P
Prime Minister of Canada



PRIME MINISTER · PREMIER MINISTRE

November 25, 2020

Dear Friends:

I am pleased to extend my warmest greetings to everyone attending the 2020 Bloom Burton Award Gala.

This annual event honours significant contributions to Canada's healthcare sector. I join with you congratulating this year's finalists for the 2020 Bloom Burton Award: Dr. Gordon Keller, Dr. Arun Menawat, and Dr. Simon Pimstone. Your achievements make you most deserving of this special recognition.

It has been a challenging year so far. The COVID-19 pandemic has made planning and hosting events especially difficult. That is why I would like to thank the dedicated organizers for making this awards gala virtual so that it could still take place. You can take pride in your commitment to recognizing, supporting and empowering innovation.

Please accept my best wishes for an engaging and memorable event.

Sincerely,



The Rt. Hon. Justin P.J. Trudeau, P.C., M.P.
Prime Minister of Canada



Premier of Ontario - Première ministre de l'Ontario



DOUG FORD

Premier of the Province of Canada



Premier of Ontario - Premier ministre de l'Ontario

November 25, 2020

A MESSAGE FROM PREMIER DOUG FORD

Hello and good evening to everyone taking part in the Bloom Burton Award Gala. Tonight, we gather for this virtual gala to recognize the scientists, inventors, entrepreneurs, policy makers and leaders who made the greatest contribution to Canada's health care sector in the past year.

I want to congratulate this year's finalists: Gordon Keller of BlueRock Therapeutics, Arun Menawat, of Profound Medical and Simon Pimstone of Xenon Pharmaceuticals. We have some of the best minds working in our health care industry, and their achievements are proof of that.

I applaud the people at Bloom Burton & Co. for organizing this terrific event, and for their commitment to celebrating excellence in the Canadian health care sector.

As you know, the human health life sciences sector plays a critical role in our province's economy, providing thousands of high-quality jobs and generating more than \$53.2 billion annually in revenue. Our government is working with life sciences partners to further unlock the potential of the sector through the development of a Life Sciences Strategy that includes health care procurement reform and data modernization. Through the Better for People, Smarter for Business Act, our government is further reducing regulatory burdens and encouraging investment in the life sciences sector.

As we work to get Ontario back on track, we will continue to work with our industry partners to find innovative ways to strengthen our health care system.

Best wishes for a memorable evening.

A handwritten signature in black ink, appearing to read "Doug Ford".

Doug Ford
Premier



JOHN TORY
Mayor of Toronto



Message from the Mayor

It is my pleasure to extend greetings and a warm welcome to everyone participating in the virtual Bloom Burton Award Gala.

This virtual ceremony will honour talented individuals who have made valuable contributions to Canada's innovative healthcare industry. While you won't be able to gather in person to celebrate, due to the current situation, I am pleased you are able to connect online. Thank you to the event organizers for bringing this event online so that participants can gather and to honour all of this year's winners. Congratulations to all of this year's winners who have helped advance Canada's healthcare sector.

Thank you to Bloom Burton & Co. for providing a platform to recognize those whose hard work and dedication have helped advance Canada's innovative healthcare industry.

On behalf of Toronto City Council, please accept my best wishes for a memorable virtual event.

Yours truly,

A handwritten signature in blue ink, appearing to read "John Tory". The signature is fluid and cursive, with a long, sweeping tail.

John Tory
Mayor of Toronto

BLOOM BURTON AWARD GALA

Bestowed annually, the Bloom Burton Award honours an individual scientist, inventor, executive, entrepreneur, industry leader, or policy maker who made the greatest contribution to Canada's innovative healthcare industry in the previous year.

Nominees for this year's award were accepted from the biotechnology, pharmaceutical, medical device, diagnostic/imaging, research instrumentation, consumer health, services and healthcare IT sectors, and equal consideration was given to contributions across all stages of development - from discovery to commercial end markets.

The Bloom Burton Award winner will be chosen from an esteemed panel of judges, all of whom are respected international leaders in healthcare investment, entrepreneurship and journalism.



GORDON KELLER

Scientific Co-founder,
BlueRock Therapeutics



ARUN MENAWAT

CEO & Chairman,
Profound Medical



SIMON PIMSTONE

CEO,
Xenon Pharmaceuticals

FINALISTS

13 Finalists

GORDON KELLER



GORDON KELLER

Scientific Co-founder,
BlueRock Therapeutics

Dr. Gordon M. Keller is the Director of the McEwen Stem Cell Institute at the University Health Network, a Senior Scientist at the Princess Margaret Cancer Centre, a Professor in the Department of Medical Biophysics at the University of Toronto, and holds the Tier I Canada Research Chair in Embryonic Stem Cell Biology. Dr. Keller received his PhD in Immunology at the University of Alberta in 1979 and completed his post-doctoral fellowship at the Ontario Cancer Institute in Toronto in 1983. He subsequently held scientist positions in Switzerland, Austria and the United States before returning to Canada as the inaugural director of the McEwen Centre for Regenerative Medicine in 2007.

Dr. Keller's research for the past three decades has centered on understanding the regulatory pathways that control the differentiation of pluripotent stem cells to different cell types in the Petri dish. The long-term goal of this work is to produce functional human cells that can be used to develop new cell-based therapies to treat a range of degenerative diseases. Over the years, Dr. Keller's lab has pioneered the use of developmental biology guided strategies to generate different types of blood cells, heart cells, liver cells, pancreatic cells and cartilage-forming cells from human pluripotent stem cells. His research program is currently focussed on testing some of these different cell types in pre-clinical models of human disease. Dr. Keller has 158 peer-reviewed publications and 43 non-peer reviewed publications.

Over his career, Dr. Keller has been the recipient of notable honours and awards. The most recent (2019) is the prestigious Ogawa-Yamanaka Stem Cell Prize from the Gladstone Institute for his pioneering work on guiding the differentiation of human pluripotent stem cells into multiple cell types. In 2017, he was awarded the Inventor of the Year at UHN.

FINALISTS

From 2005 to 2006, Dr. Keller served as President of the International Society for Stem Cell Research, and is currently a member of its board of directors (ex-officio).

Dr. Keller has numerous commercialization endeavours. He holds over 20 patents and 8 patent licenses. He is a scientific co-founder of BlueRock Therapeutics (\$1B), a biotechnology company focussed on developing pluripotent stem cell-based therapies to treat heart failure and Parkinson's disease. He currently serves as a scientific advisor for the company. Additionally, Dr. Keller is a member of the scientific advisory board of VistaGen Therapeutics and a member of board of Anagenesis Biotechnologies.

16 Finalists

ARUN MENAWAT



ARUN MENAWAT

Chairman & CEO,
Profound Medical

Dr. Arun Menawat is Chairman and CEO of Profound Medical Inc., a commercial stage medical technology company that markets real-time MRI-guided thermal ultrasound systems for incision-free ablation of abnormal or cancerous tissue. Profound's key product is the TULSA-PRO therapeutic system, designed for precise and customizable ablation of diseased prostate tissue.

Before joining Profound, Arun served as the Chairman and CEO of Novadaq Technologies Inc. for 13 years, guiding the company from a startup to one of the fastest growing, NASDAQ listed medical technology companies in North America, with a market cap of mostly over one billion USD during the final three years of his leadership. Earlier, Arun served as President of Cedara Software Corp., a company that developed the industry's first medical imaging software platform. Today, Cedara's imaging platform and its big data collection are part of IBM's Watson Health.

He obtained a Ph.D. in Chemical Engineering from the University of Maryland, and an Executive MBA from the J.L. Kellogg School of Management, Northwestern University. In 2014, he was named the EY Ontario Entrepreneur of the Year in the health sciences category.

FINALISTS

SIMON PIMSTONE



SIMON PIMSTONE

CEO,
Xenon Pharmaceuticals

Dr. Pimstone has served as a member of the Xenon Pharmaceuticals Board since November 1996, as the Chief Executive Officer since January 2003 and as the President from January 2003 to March 2018. Since 2012, Dr. Pimstone has been a Consultant Physician at the University of British Columbia Hospital, Cardiology Clinic, and since 2014, he has held the position of Clinical Associate Professor at the University of British Columbia, Division of General Internal Medicine.

Currently, Dr. Pimstone is an Investigator at the Centre for Heart Lung Innovation (HLI) research centre. Dr. Pimstone currently serves as chair of the board of Eupraxia Pharmaceuticals Inc., TopiRx Pharmaceuticals, and Alpha9 Theranostics Inc., three private specialty pharmaceutical companies, where he has served as a director since 2012, 2019, and 2020 respectively.

Dr. Pimstone holds an MBChB from the University of Cape Town, a FRCPC from the University of British Columbia, and a Ph.D. from the University of Amsterdam in cardiovascular genetics. Previously, Dr. Pimstone was director and chair of the board of directors of LifeSciences British Columbia, a non-profit industry association that supports the life science community, and a former director of the Providence Healthcare Research Trust, BC Advantage Life Sciences Fund, Centre for Molecular Medicine and Therapeutics, BIOTECanada, and BC Health Research Strategy Advisory Board of the Michael Smith Foundation for Health Research.

FINALISTS

JUDGING PANEL

MICHAEL ALTMAN

Managing Director,
Perceptive Advisors

CHRIS ARENDT

Head, Oncology Therapeutic
Area Unit, Takeda

KAREN BERNSTEIN

Co-Founder & Chairman,
BioCentury Inc.

CARL GORDON

Managing Partner,
OrbiMed Advisors

DENNIS PURCELL

Founder & Senior Advisory,
Aisling Capital

MELINDA RICHTER

Global Head of Johnson &
Johnson Innovation, JLABS

CAMILLE SAMUELS

Partner,
Venrock



MICHAEL ALTMAN

Managing Director,
Perceptive Advisors

Michael Altman joined Perceptive in 2007 and is a managing director on the investment team. His focus is on medical devices, diagnostics, digital health and Specialty Pharmaceuticals. He is also a member of the investment committee for the credit opportunities fund. Additionally, Michael serves as the CFO and Director of ARYA Sciences Acquisition Corp II & III. Prior to Perceptive he was a healthcare trader and analyst at First New York Securities. Michael graduated from the University of Vermont with a B.S. in Business Administration. Michael serves on the board of directors for Lyra Therapeutics and Vitruvius Therapeutics.

JUDGES

JUDGES

CHRIS ARENDT

Head, Oncology Therapeutic Area Unit,
Takeda

Based at Takeda's Cambridge research campus, Christopher Arendt is a member of Takeda's Research Senior Leadership Team responsible for Immunology and Oncology research through to early clinical proof-of-concept. Working with a global network of outstanding biotech and academic collaborators, his teams in Cambridge, San Diego and Japan are seeking to translate innovative scientific discoveries into modality-diverse medicines that address the needs of specific patient populations.

Prior to joining Takeda in 2015, Christopher Arendt spend more than 13 years at Sanofi, where he led teams advancing novel immunotherapies for cancers and inflammatory diseases to the clinic. He obtained his PhD in Immunology from the University of Alberta and carried out his postdoctoral training with Dan Littman at the Skirball Institute of Biomolecular Medicine at NYU Medical Center, supported by the Medical Research Council of Canada and Howard Hughes Medical Institute.





KAREN BERNSTEIN

Co-Founder & Chairman,
BioCentury Inc.

Karen is Co-Founder and Chairman of BioCentury Inc. and was Editor in Chief from October 1992 to August 2015.

She is a director at Ovid Therapeutics Inc., which is developing drugs for orphan diseases of the brain, and at Codiak Biosciences Inc., which is engineering exosomes to target new therapeutic spaces. Karen also serves on the board of trustees of the Keck Graduate Institute of the Applied Life Sciences and is a member of the board of advisors of KGI's School of Pharmacy. She serves on the Board of Overseers of Scripps Research.

Karen holds a Ph.D. in Political Science from Stanford University and a B.A. in Politics and History from Brandeis University, where she served for many years as a member of the Brandeis University Science Advisory Council.

In 2005, the annual gathering of biotechnology chief executive officers at The Biotech Meeting in Laguna Niguel, Calif., inducted Karen into their Hall of Fame, citing her lifetime contribution to the biotech community. In 2007, Karen received a Special Recognition award at the American Liver Foundation's Salute to Excellence, honoring individuals who have made an outstanding contribution to biotechnology and medical innovation. In 2013, she was named as one of the 100 Women of Influence in Silicon Valley by the Silicon Valley Business Journal. In 2015, Scientific American named Karen as one of The WorldVIEW 100 most influential people in biotech today. In 2016, she was named Commentator of the Year by the European Mediscience Awards.

JUDGES

JUDGES

CARL L. GORDON

Managing Partner,
OrbiMed Advisors

Carl L. Gordon, Ph.D., CFA, is a founding Partner and Co-Head of Global Private Equity at OrbiMed. For the last six years (2014 to 2019) Forbes® Magazine named Dr. Gordon one of the top 100 venture capitalists in the world when it placed him on the “Forbes Midas List”. He received a Ph.D. in Molecular Biology from the Massachusetts Institute of Technology (1993) and a Bachelor of Arts Degree from Harvard College (1987), and was a Fellow at The Rockefeller University from 1993 to 1995.





DENNIS PURCELL

Founder & Senior Advisory,
Aisling Capital

Mr. Purcell is the original Founder of Aisling Capital LLC. Previously, he served as the Senior Managing Partner. Prior to Aisling Capital, Mr. Purcell served as Managing Director of the Life Sciences Investment Banking Group at Chase H&Q (formerly Hambrecht & Quist, “H&Q”) for over five years. While at H&Q, he was directly involved with over two hundred completed transactions and supervised over \$10 billion of financing and advisory assignments in the pharmaceutical, biotechnology and medical products industries. During his tenure, BioWorld and other industry publications cited H&Q as the leading underwriter of life sciences securities. Prior to joining H&Q, Mr. Purcell was a Managing Director in the Healthcare Group at PaineWebber, Inc.

Mr. Purcell is a frequent commentator on the industry and has been honored in the “Biotech Hall of Fame” by Genetic Engineering News, named to the Biotechnology All-Stars list by Forbes ASAP, honored as one of the top 50 Irish-American businessmen and cited as one of the top 100 contributors to the biotechnology industry.

Mr. Purcell has served as a director of Aton Pharma (acquired by Merck), Bridge Pharmaceuticals (acquired by Pharmaron), Cengent Therapeutics, Dynova Laboratories, Paratek Pharmaceuticals, Valentis and Xanodyne Pharmaceuticals. Mr. Purcell also served as a member of the Section Governing Board at BIO (“Biotechnology Innovation Organization”), the Irvington Institute and on the Board of L.E.K. Consulting. He currently sits on the Boards of Real Endpoints, Summus Global, Inc., BioScience Managers, and Ichnos Sciences. He sits on the Editorial Advisory Board at Life Science Leader Magazine; Member of the Board at NYBIO Association; Board Member at The University of Delaware Investment Visiting Committee as well as a member of the Biopharmaceutical Innovation Board at the University of Delaware.

Mr. Purcell received his M.B.A. from Harvard Business School and his B.S. in Accounting from the University of Delaware.

JUDGES

JUDGES

MELINDA RICHTER

Global Head of Johnson & Johnson Innovation,
JLABS

As Global Head of Johnson & Johnson Innovation, JLABS (JLABS), Melinda Richter fosters the Johnson & Johnson Family of Companies external R&D engine and supports the innovation community by creating capital-efficient commercialization models that give early stage companies a big company advantage. By providing infrastructure, services, educational programs and networks in global hotspots, JLABS is the best place to start a company working in healthcare, with a specific emphasis on Johnson & Johnson's sectors: consumer, medical device and pharmaceuticals.

Prior to joining JLABS, Melinda was Founder and CEO of Prescience International, an award-winning firm dedicated to accelerating research to the patient. Melinda founded Prescience after she had a medical emergency that left her questioning the efficiency and efficacy of the healthcare system. With the tenacity and resolve of a patient looking for a better solution, she set out to create a better model, which now forms the basis for JLABS' operational infrastructure. Prior to starting Prescience, Melinda held posts across a variety of functional areas with a global corporation, Nortel Networks, in locations such as Research Triangle Park, New York, Toronto, London, Hong Kong and Beijing before arriving in San Francisco. She also initiated, raised capital and secured large corporate deals for several companies in both the life science and technology space. She holds a Bachelor of Commerce from the University of Saskatchewan in Canada and a MBA from INSEAD in France. Melinda is an active board member and Treasurer of the California Life Sciences Association (CLSA).





CAMILLE SAMUELS

Partner,
Venrock

Cami Samuels focuses on healthcare with an emphasis on biotech, medical devices, and consumer health. She currently serves on the board of Iris, Unity (UBX), and XCaliber – and previously served on the board of several other Venrock companies including Corvidia (sold to Novo Nordisk), Spirox (acquired by Stryker via Entellus) and RegenXBIO (RGNX). Prior to Venrock, Cami was a Managing Director at Versant Ventures where she supported many companies including Genomic Health (GHDX), Jazz (JAZZ), Kythera (KYTH/acq by Allergan), Novacardia (acq by Merck), and ParAllele (acq by Affymetrix). Before her venture career, Cami worked in business development at Tularik (acq by Amgen). During her early career, Cami worked in corporate development at Genzyme and Millennium Predictive Medicine and was a management consultant at LEK Consulting. Cami earned her Bachelor’s degree in Biology from Duke University and an MBA from Harvard Business School, where she graduated as a Baker Scholar.

JUDGES



BLOOM BURTON & CO.
HEALTHCARE INVESTOR CONFERENCE

APRIL 20 - 21, 2021



BLOOM BURTON
AWARD GALA

VIRTUAL EXPERIENCE